Submitting OIG:
Report Description:
For a covered outpatient drug to be eligible for Federal Medicaid reimbursement, the manufacturer must enter into a rebate agreement administered by the Centers for Medicare & Medicaid Services (CMS) and pay quarterly rebates to the States. Previous OIG audits found that States did not always bill and collect all rebates due for drugs administered by physicians to enrollees of Medicaid managed-care organizations (MCOs).
Date Issued:
Tuesday, April 7, 2020
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
A-02-18-01016
Component, if applicable:
Centers for Medicare & Medicaid Services
External entity, if applicable:
State of New York
Location(s):
NY
United StatesType of Report:
Audit
Questioned Costs:
$10,885,620
Funds for Better Use:
$0
Number of Recommendations:
3
View Document:
Attachment | Size |
---|---|
21801016.pdf | 1.31 MB |
Additional Details Link: